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Objectives. Cytokines play an important role in left ventricular remodeling consequent to myocardial ischemia. The aim of this
study was to correlate cytokine production and lymphocyte apoptosis to post-ischemic left ventricular remodeling in patients
aﬀected by acute myocardial infarction (AMI) undergoing primary cutaneous angioplasty (PCI). Methods. In 40 patients, aﬀected
by AMI and undergoing PCI, we evaluated peripheral blood mononuclear cells (PBMCs), tumor necrosis factor-alpha (TNF-
α) and interleukin 10 (IL10) production and apoptosis on day 1, day 3, day 7, 1 month and 6 months after PCI. Patients
were divided into two subgroups of remodeling or not remodeling by echocardiographic criteria. Results. In the subgroup of
remodeling patients, at each timepoint TNF-α production was increased signiﬁcantly in comparison with the subgroup of not
remodeling patients. IL10 production was statistically lower in remodeling subjects than in not remodeling ones 1 and 6 months
afterreperfusion.Therewerenodiﬀerencesbetweenthetwogroupsasregardslymphomonocyteapoptosis.Conclusions.Wefound
an increased production of pro-inﬂammatory cytokine TNF-α and a corresponding decrease of anti-inﬂammatory/regulatory
cytokine IL10 in remodeling patients and we concluded that this cytokine imbalance resulted in pro-inﬂammatory eﬀects which
might contribute to the progression of left ventricular remodeling.
1.Introduction
Inﬂammatory response and cytokine elaboration are inte-
gral components of the host immune response to tissue
injury and play an active role after myocardial infarction.
The degree of the inﬂammatory response is an important
determinant of the host’s outcome because it can lead to
healing and restoration of function, to acute cardiac rupture,
or chronic dilatation [1].
Myocardial remodeling can be deﬁned as molecular,
cellular, and interstitial changes within the myocardium that
result in changes in left ventricular size and function [2, 3]:
one of the predominant features of myocardial remodeling is
left ventricular dilatation [4], whose progression aﬀects the
survival of the patients with an increased mortality due to
heart failure [5].
Upregulation of pro-inﬂammatory cytokines, such as
TNFα, interleukin 1beta (IL1β), and IL6, usually unex-
pressed in the normal heart, has been clearly shown both in
animal and human models during myocardial infarction [6–
8]; the acute intramyocardial gene expression of TNFα,I L 1 β,
and IL6 involves both the infarct area and the noninfarcted
myocardium, but it begins to decrease towards baseline after
1w e e k[ 9]. If the infarct size is large or if there are ongoing
myocardial stress factors, the cytokine gene expression may
remain elevated or may recrudescence as a second wave of
cytokine activation [10]; the levels of late cytokine activation
in the noninfarctual region correlate the best with the
eventual left ventricular end-diastolic diameter measured
at 20 weeks after infarction [1, 11]. More recently, it has
been shown that IL10, a pleiotropic cytokine with potent2 Mediators of Inﬂammation
anti-inﬂammatory eﬀects in many cells lines [12], may have
in some in vitro ischemia-reperfusion models a protective
role through the suppression of the acute inﬂammatory
process: in particular IL10 is able to abrogate TNFα-induced
vascular smooth muscular cell (VSMC) growth [13].
On the basis of these premises, we studied the role of
peripheral cytokine production in myocardial remodeling
and functioning in patients aﬀected by acute myocardial
infarction undergoing PCI. In particular, we evaluated
PBMCs TNFα a n dI L 1 0p r o d u c t i o na sw e l la sl y m p h o m o n o -
cyteapoptosisatdiﬀerenttimepointsaftertheacuteischemic
event and we correlated immune activation to postischemic
left ventricular remodeling assessed with echocardiographic
study.
2.MaterialsandMethods
2.1. Patients. We enrolled 40 patients (mean age 64 years,
range 48–78) aﬀected by acute ST-elevation myocardial
infarction (STEMI) undergoing PCI within 12 hours from
the onset of symptoms. Patients were successively divided in
two groups of left ventricular remodeling (R, n = 20) and no
left ventricular remodeling patients (NR, n = 20) according
the presence or absence of left ventricular dilation evaluated
at 6 months after infarction with echocardiographic criteria
(Tables 1 and 2). Patients with a history of previous
myocardial infarction, previously known coronary artery
disease, heart failure, arrhythmias, valvulopathies, chronic
or acute inﬂammatory or infectious disease, neoplasm, liver,
and renal disease were excluded from the study. The same
conditions, particularly acute or chronic infections, induced
the exclusion of patient from the study in the follow-up at
the various timepoints. Patients did not assume drugs that
could interfere with immune cell functions in any phase of
the study; only acetaminophen was occasionally assumed by
some patients (3 remodeling patients and 4 not remodeling
subjects) and just for no longer than a few days and not in
coincidence with blood sampling. Fifteen normal subjects
matched for age and sex were also studied as regards to
cell cultures. All patients gave their informed consent to be
included in the study. The procedure was approved by the
ethical committee of our Hospital and the study was done
according the ethical standards for experiments in human
subjects established by the Declaration of Helsinki.
2.2. Echodoppler Ultrasound Study. The study was done
using Vivid seven echocardiograph (General Electrics)
equipped with 2.5MHz transducers. Bidimensional images,
echo-Doppler ultrasound, and color-Doppler ultrasound
spectra were analyzed using a computerized system (Echo-
Dat; Medicine Inc.software). The ejection fraction (EF), left
ventricular end-systolic (LVESV) and end-diastolic volume
(LVEDV), were recorded as indices of ventricular function.
EF was calculated by the modiﬁed Simpson’s method in
apical four- and two-chamber views [14, 15].
Postischemic left ventricular remodeling was deﬁned
as a 20% increase of left ventricular end-diastolic and
end-systolic volumes at the end of follow-up (6 months)
compared with baseline measures (day 1) [16].
2.3. Cell Isolation and Culture. PBMCs were obtained from
the patients’ and controls’ heparinized whole blood at the
following timepoints: day 1, day 3, day 7, 1 month, and
6 months after reperfusion. PBMCs were isolated by den-
sity gradient centrifugation over Histopaque 1077 (Sigma-
Aldrich, Milano, Italy) and cultured in RPMI 1640 medium
supplemented with fetal calf serum (10%), L-glutamine
(2mM),andpenicillin-streptomycin(100U/mL,100μg/mL,
Gibco, Paisley, UK).
2.4. TNFα and IL10 Production by PBMC. 1 × 106 PBMCs
were put in culturein complete medium and stimulated with
LPS (E.coli, 1μg/mL, Sigma) for 24 hours.
2.5. Quantiﬁcation of TNFα and IL10. Cell culture media
harvested were tested for TNFα a n dI L 1 0p r o d u c t i o nb y
ELISA using ELISA microtiter plates (Corning Easy Wash,
Celbio, Milano, Italy) coated overnight with 2μg/mL anti-
TNF-α or anti-IL10 capture mAb (Pharmingen) in 0.1M
Na2HPO4 pH 9 buﬀer and blocked with PBS/Tween. A
biotin-labeled anti-TNFα or anti-IL10 detecting antibody
(Pharmingen) at 1μg/mL in PBS/10% fetal calf serum was
used. The plates were developed using avidin-HRP (Vector,
Burlingame, CA, USA) and 2,2 azino-bis substrate (Sigma).
The lower limit of detection was 15.6pg/mL.
2.6. Apoptosis Assays. After 20 hours of culture, lymphocyte
apoptosis was assessed through the binding of Annexin
V/uptake of propidium iodide by ﬂow cytometry (PAS,
Partec, Germany) using the apoptosis detection kit annexin
V-FITC (Dako, Glostrup, Denmark). Forward light scatter
characteristics of living cells were used to delete debris from
the analyses. Logarithmic ﬂuorescence intensity of annexin
V-FITC was plotted versus the ﬂuorescence intensity of
propidium iodide (PI) in a dot plot. Data from 10.000
lymphocytes gated on forward scatter versus side scatter
properties were analysed for each plot and the percentage of
annexin positive- and PI negative-cells (early apoptotic cells)
was determined. Quadrants were estimated by comparison
of unstained and annexin V-FITC/PI stained samples.
2.7.StatisticalAnalysis. Dataarepresentedasmedian±stan-
dard error of the mean. The Mann Whitney U-test was used
to compare data obtained in patients undergoing ventricular
remodeling to those obtained in patients not undergoing
ventricular remodeling and in controls. The Wilcoxon test
was used to compare data obtained in the same group of
patients at diﬀerent timepoints. P<. 05 was considered
signiﬁcant. Spearman’s correlation coeﬃcient was employed
to determine putative linear relations between changes in the
measurable echographic and biological parameters.
3. Results
3.1. Left Ventricular Remodeling. Table 1 shows baseline
and clinical characteristics of patients divided in the two
groups of patients who showed left ventricular remodeling,
compared with patients who not undergo left ventricularMediators of Inﬂammation 3
Table 1: Baseline characteristics of patients.
Remodeling patients (n = 20) Not remodeling patients (n = 20) P
Age, y 64 ±76 3 ±9N S
Male:female 13/7 12/8 NS
Risk factors, n (%)
Familiarity 12 (60%) 10 (50%) NS
Smoke 4 (20%) 6 (30%) NS
Hypertension 2 (10%) 3(15%) NS
Diabetes 0 0 NS
Hypercolesterolemia 4 (20%) 4 (20%) NS
Anterior and/or lateral infarction 14 (70%) 13 (65%) NS
Q wave at admission 12 (60%) 10 (50%) NS
Time to reperfusion (hour) 5 ±45 ±3N S
Troponin peak 4 ± 23 .5 ±1N S
Treatment at discharge
Antiaggregants 20 (100%) 20 (100%) NS
B-blockers 12 (60%) 10 (50%) NS
ACE-inhibitors 20 (100%) 20 (100%) NS
Diuretics 16 (80%) 15 (75%) NS
Nitrates 12 (60%) 12 (60%) NS
Statins 20 (100%) 20 (100%) NS
Baseline echocardiographic features
LVEDV (mL) 93 ± 79 7 ± 6N S
LVESV (mL) 53 ± 75 6 ± 7N S
EF (%) 44 ± 44 2 ± 5N S
LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; EF: ejection fraction. NS: not signiﬁcant; ∗∗P<. 01.
Table 2: Echocardiographic evaluation.
Pts with left ventricular remodeling Pts without left ventricular remodeling
Day 1 6 months Percent variation Day 1 6 months Percent variation
LVEDV (mL) 93 ±7 128 ±9 +38% ±79 7 ±69 3 ±7 −4% ±2
LVESV (mL) 53 ±77 5 ±7 +44% ±75 6 ±74 5 ±6 −21% ±3
EF (%) 44 ±44 2 ±4 −5% ±24 2 ±55 2 ±4+ 2 5 % ±6
LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; EF: ejection fraction.
remodeling. As shown in the table, the two subgroups
of patients were very similar and no diﬀerences were
present as regards risk factors, characteristics of infarction,
and drug assumption. Table 2 shows the echocardiographic
characteristics of the same groups of patients which were
used to distinguish remodeling and not remodeling subjects
on the basis of left ventricular dilation, deﬁned as an
increaseinenddiastolicvolume>20%,asassessedbyauthors
[16].
3.2. Patients Undergoing Left Ventricular Remodeling Showed
an Increased Production of TNFα. Patients with postischemic
left ventricular remodeling showed on day 1 after PCI an
increased production of TNFα after LPS stimulation in
comparisonwithpatientswhodidnotundergopostischemic
left ventricular remodeling (P<. 05). They also produced
increased amount of TNFα in comparison with controls
(P<. 05), whereas there was no diﬀerence between
controls and patients who did not undergo left ventricular
remodeling (Figure 1). The increased TNFα production after
LPS stimulation was still detectable in remodeling subjects in
comparisonwithnotremodelingonesonday3(P<. 01)and
day 7 (P<. 0 1 )a f t e rP C I ,a sw e l la s1m o n t h( P<. 01) and 6
months (P<. 05) after this procedure (Figure 2).
In patients undergoing left ventricular remodeling we
could not ﬁnd any signiﬁcant diﬀerence concerning LPS-
stimulated TNFα production amongst the diﬀerent time-
points; similar results were obtained in those patients who
did not develop left ventricular remodeling (Figure 3).
3.3. Patients Undergoing Left Ventricular Remodeling Showed
a Decreased Production of IL10. When we analyzed LPS-
induced IL10 production, on day 1 after reperfusion we
did not ﬁnd any diﬀerence between left ventricular remod-
eling subjects and not remodeling subjects. However in
both groups IL10 production was signiﬁcantly reduced in4 Mediators of Inﬂammation
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Figure 1: In patients developing left ventricular remodeling after
myocardial infarction (R, n = 20) lymphomonocyte production
of TNF-α in response to LPS was increased in comparison with
patients not developing left ventricular remodeling (NR, n = 20)
and in comparison with controls on day 1 after reperfusion (∗P<
.05).
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Figure 2: In patients developing left ventricular remodeling after
myocardial infarction (R, n = 20) lymphomonocyte production
of TNF-α in response to LPS was increased in comparison with
patientsnotdevelopingleftventricularremodeling(NR,n = 20)on
day 3, on day 7, 1 month, and 6 months after reperfusion (∗P<. 05,
∗∗P<. 01).
comparison with controls (P<. 001, Figure 4). On day
3 and day 7 IL10 production was not diﬀerent between
remodelingandnotremodelingsubjects,but1and6months
after reperfusion, IL10 production was statistically lower in
subjects developing left ventricular remodeling than in not
remodeling ones (P<. 05, P<. 001, Figure 5).
In patients undergoing left ventricular remodeling we
foundthatLPS-stimulatedIL10productionincreasedonday
3 and on day 7 in comparison with day 1 (P<. 05) but
returned to levels similar to day 1, 1 and 6 months after
reperfusion (Figure 6). On the contrary, in not remodeling
patients, IL10 production was signiﬁcantly increased in
comparison with day 1 after reperfusion at every timepoint
(P<. 001) and it was still statistically higher 6 months after
reperfusion when it reached values comparable to normal
controls (Figure 6).
3.4. Lymphocyte Apoptosis Was Not Increased in Patients
Undergoing Left Ventricular Remodeling. When we analyzed
spontaneous lymphocyte apoptosis in vitro after 24 hours
of cultures, we found that the percentage of annexinV+PI-
lymphocytes was not signiﬁcantly diﬀerent between remod-
eling patients and not remodeling ones (28.5 ± 10 versus
30±8%), overlapping thevaluesobtained in normalsubjects
(25 ±11%) (not shown).
3.5. Linear Regression Analysis in the Whole Cohort. Our
ﬁndings of a diﬀerent pro-inﬂammatory/anti-inﬂammatory
imbalance in the studied groups according to remodeling
trend were conﬁrmed by the linear regression analysis
between TNFα, IL10, and LVEDV in the whole cohort
(Figure 7).Indeed,adirectlinearrelationwasfoundbetween
TNFα levels and LVEDV volume (r = 0.28, P = .039)
and between percent changes of both parameters (r = 0.31,
P = .018) at six months (Figure 7). IL10 levels were inversely
related to LVEDV at day 1 (r =− 0.41, P = .011) that
was conﬁrmed at 6 months (r =− 0.37, P = .019) also
when analyzed as percent changes (r =− 0.38, P = .021)
(Figure 7).
4. Discussion
Postischemicleftventricularremodelingisacomplexprocess
that takes place after myocardial infarction both in the
region aﬀected by acute ischemia and in adjacent areas: it is
characterized by reduction of myocytes in the infarct area,
chamber dilatation, ﬁbrosis and scar formation, collagen
dissolution and excessive interstitial matrix accumulation,
increased wall stress, and myocyte hypertrophy [17]. It
results in ventricular geometric alterations and sustained
deterioration in cardiac function [4, 5]. The development of
ventricular remodeling involves a number of diﬀerent mech-
anisms, including neurohormonal stimulation, enzymes, ion
channels, oxidative stress, mechanical stress, growth factors,
and inﬂammatory cytokine production [1].
Recent clinical and experimental studies have suggested
that, among inﬂammatory cytokines, increased release of
TNFα can contribute to the progression of left ventricular
remodeling and dysfunction [18]. In adult rats, surgically
implanted with an osmotic minipump infusing TNFα for
5 days in order to reach plasma levels comparable to those
reported in clinical heart failure, a decrease in left ventricular
fractional shortening occurred and left ventricular end dias-
tolic diameter increased by over 25% when compared withMediators of Inﬂammation 5
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Figure 3: Both in patients developing left ventricular remodeling after myocardial infarction (n = 20) and in patients not developing
left ventricular remodeling (n = 20) lymphomonocyte production of TNF-α in response to LPS was not diﬀerent amongst the diﬀerent
timepoints evaluated.
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Figure 4: Both in patients developing left ventricular remodeling
after myocardial infarction (R, n = 20) and in patients not devel-
oping left ventricular remodeling (NR, n = 20) lymphomonocyte
production of IL10 in response to LPS was reduced in comparison
with controls on day 1 after reperfusion (∗∗∗P<. 001).
time-matched controls [19]. In a transgenic mouse model,
myocardial TNFα overexpression caused increased systolic
and diastolic left ventricular volumes and a reduced collagen
crosslinking in myocardium [20]. Since activation of TNFα
receptors increases production of matrix metalloproteinases,
onemechanismbywhichTNFαcaninﬂuenceleftventricular
remodeling appears to be induction of myocardial matrix
metalloproteinases and subsequent degradation of extracel-
lular matrix components [20].
We found that in patients undergoing postischemic left
ventricular remodeling in vitro TNFα production imme-
diately after the ischemic event was statistically increased
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Figure 5: In patients developing left ventricular remodeling after
myocardial infarction (R, n = 20) lymphomonocyte production of
IL10 in response to LPS was reduced in comparison with patients
not developing left ventricular remodeling (NR, n = 20) 1 month
and 6 months after reperfusion (∗P<. 05 and ∗∗∗P<. 001, resp.).
in comparison with patients who did not develop left
ventricular remodeling. More interestingly, 6 months after
myocardial infarction, in the same group of patients, TNFα
production was persistently higher than that in the patients
not undergoing left ventricular remodeling. This ﬁnding
agrees with other authors studies which assessed the role of
TNFα both in myocardial infarction and in left ventricular
remodeling; particularly, it has been found that the levels of
late cytokine activation in the noninfarctual region correlate
the best with the eventual left ventricular end-diastolic
diameter measured at 20 weeks after infarction [7, 8]. Our
data suggest that peripheral cytokine production reﬂects
what happens in myocardium in which the persistence of
cytokine activation in response to mechanical, oxidative and6 Mediators of Inﬂammation
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Figure 6: In patients developing left ventricular remodeling after myocardial infarction (n = 20) lymphomonocyte production of IL10 in
response to LPS was increased on day 3 and day 7 after reperfusion in comparison with day 1 (∗P<. 05). In patients not developing left
ventricular remodeling after myocardial infarction (n = 20) lymphomonocyte production of IL10 in response to LPS was increased on day
3, on day 7, 1 month, and 6 months after reperfusion in comparison with day 1 (∗∗∗P<. 001).
neurohormonal stress initiates a vicious cycle. In patients
undergoing ventricular remodeling secondary to ischemic
cardiac disease, Otero et al. could not ﬁnd increased serum
levels of TNFα in comparison with those aﬀected by dilated
cardiomyopathy, whereas they found increased levels of
sTNF-RI and sTNF-RII [21]; the diﬀerent results obtained
in this study in comparison with ours could be due to the
fact that we evaluated TNFα in vitro production which does
not necessary correspond to increased serum levels of this
cytokine.
We also studied IL10 in vitro production because
IL10 is an anti-inﬂammatory cytokine which modulates
matrix metalloproteinase expression and suppresses pro-
inﬂammatory cytokine synthesis, such as TNFα [12, 22].
Numerous recent experimental studies have shown that
either systemic or local IL10 gene transfer attenuates
atherogenesis and aﬀects processes associated with lesion
progression [23, 24]. Moreover, in a large cohort of patients
aﬀected by acute coronary syndromes, elevated IL10 serum
levels have been associated with a more favourable prognosis
[25]. However, at least in animal models, IL10 does not
seem to play a critical role in infarct healing and left
ventricular remodeling, because IL10 gene disruption does
not alter ﬁbrous tissue deposition and dilatative remodeling
of the infarcted heart in a mouse model [26]. Similarly,
the pretreatment of cardiac ﬁbroblasts with IL10 does not
inhibit chemokine synthesis in response to TNFα [26]. In
our study, IL10 production was signiﬁcantly decreased in
comparison with normal subjects in both patients under-
going left ventricular remodeling and those not undergoing
left ventricular remodeling, immediately after myocardial
infarction. However, in those patients who did not develop
left ventricular remodeling IL10 increased progressively
reaching normal levels 6 months after the acute event,
whereas in those developing left ventricular remodeling it
increased on day 3 and 7 after reperfusion but returned to
baseline levels 1 and 6 months after reperfusion. Therefore
IL10 seems to play a protective role because lower levels
several months after reperfusion are associated with left
ventricular remodeling. Such ﬁndings could be of relevance
because they add data to the body of evidence dealing with a
more complex system in vivo, in which the balance between
pro-/anti-inﬂammatory mediators is operating in cardiac
remodeling with respect to the single action of several pro-
/anti-inﬂammatory mediators as shown especially in animal
models [26].
Finally we evaluated lymphocyte apoptosis because we
found a persistent and increased production of TNFα in
ventricular remodeling patients. TNFα is able to induce
apoptosis in several cell types, including lymphocytes,
by binding to TNFR-1 that contains a death domain
[27, 28]. Moreover, in some human models, such as in
aging, both TNFα production and TNFα-induced apoptosis
are increased [29, 30]. However, spontaneous lymphocyte
apoptosis was not diﬀerent among ventricular remodeling
patients, not ventricular remodeling ones and controls. It
remains to be established whether the increased systemic
TNFα production contributes to the increased cardiomy-
ocyte apoptosis that has been found in postinfarction cardiac
remodeling, especially at the site of recent infarction but also
in unaﬀected areas to a lesser extent [31, 32].
In summary, our data analysing the cytokine network
in the complex processes of postischemic left ventricular
remodeling have conﬁrmed important disturbances in the
cell production of pro- and anti-inﬂammatory mediators; in
particular the increase of pro-inﬂammatory cytokine TNFα
is associated with the decrease of IL10 which could exert
a protective/regulatory role. It is not clear why the same
ischemic stress induces in patients with similar characteris-
tics more TNFα and less IL10 production than in others.
However we can observe that a marked imbalance between
pro-inﬂammatory and protective mechanism is generatedMediators of Inﬂammation 7
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Figure 7: Linear regression coeﬃcient (Spearman’s) between TNFα, IL10, and Echocardiographic Left Ventricular end-diastolic volume
(LVEDV) in the whole cohort (n = 40) at day 1, 6 months, and trend day 1–6 months. Each data is provided as continuous variable (day 1
and 6 months) and percent changes (trend day 1–6 months).
in patients undergoing left ventricular remodeling and we
can suggest that the lack of this important homeostatic
mechanism could inﬂuence the activation and the extent
of inﬂammatory reaction which leads to the progression of
ventricular remodeling and consequent myocardial failure.
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